Asuragen Quantidex NGS RNA Lung Cancer Kit
Asuragen has launched the QuantideX NGS RNA Lung Cancer Kit, a next-generation sequencing panel that analyzes known gene fusions, 3' and 5' imbalance markers, exon skipping events, and mRNA expression levels in non-small cell lung cancer samples. The kit is optimized for use with low-quality samples and low input samples, including from formalin-fixed paraffin-embedded and fine needle aspirations. It has also been designed to work with Asuragen's Sample-Aware bioinformatics software. According to the company, the panel can detect fusions and splice variants at 5 percent cell fraction and 1 percent cell fraction, respectively.